The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have multiple myeloma (MM). This study will look at the effectiveness and safety in participants who take ixazomib in addition to lenalidomide and dexamethasone.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
o Stem cell harvest and mobilization regimen is acceptable if clinically indicated, but must first be confirmed by the Takeda Medical Monitor.